Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Divests Canadian Business to Knight
June 9, 2025
- BMS Files Label Expansion of Sotyktu for Psoriatic Arthritis in Japan
June 9, 2025
- Tivdak Offers Valuable New Option as 2nd-Line Cervical Cancer Therapy: Oncologist
June 9, 2025
- Antibody Market to Reach 2.6 Trillion Yen in 2034: Fuji Keizai
June 9, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
- Fuso Takes Remitch Patent Case to Top Court
June 9, 2025
- Japan Ethical Drug Sales Up 1.2% in April: Crecon
June 9, 2025
- Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
- Meiji, Daito to Launch Talks on New Consortium to Stabilize Generic Supply, Boost Profitability
June 6, 2025
- Keytruda Japan’s Top-Selling Drug for 20th Month Running: Encise
June 6, 2025
- Santen’s Myopia Drug Approved in Europe
June 6, 2025
- Towa/CiRA to Launch PII/III Trial of Bromocriptine for Familial AD
June 5, 2025
- Fuji Keizai Issues 2040 Market Outlook for Dermatology, Collagen Diseases and More
June 5, 2025
- Takeda’s Adcetris Widens Label in Europe
June 5, 2025
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Dupixent’s COPD Use Expected to Benefit Patients with Allergic Symptoms: Professor
June 3, 2025
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Taiho Out-Licenses LSD1 Inhibitor to Yokohama Upstart
June 3, 2025
- Nxera-Lilly Collab Hits Key Milestone, Triggers Undisclosed Payment
June 3, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…